methionine has been researched along with plerixafor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fujii, N; Gotoh, K; Kanamoto, T; Kanbara, K; Mochizuki, K; Nakashima, H; Tamamura, H; Yoshimori, M | 1 |
1 review(s) available for methionine and plerixafor
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for methionine and plerixafor
| Article | Year |
|---|---|
Increase of R5 HIV-1 infection and CCR5 expression in T cells treated with high concentrations of CXCR4 antagonists and SDF-1.
Topics: Animals; Anti-HIV Agents; Antibodies, Monoclonal; Benzylamines; CD4 Antigens; CD4-Positive T-Lymphocytes; Chemokine CXCL12; Chemokines; Chemokines, CXC; Chlorocebus aethiops; COS Cells; Cyclams; Drug Synergism; Gene Expression Regulation; Heterocyclic Compounds; HIV Long Terminal Repeat; HIV-1; Humans; Methionine; Oligopeptides; Peptide Fragments; Receptors, CCR5; Receptors, CXCR4; Transfection; Tumor Cells, Cultured; Virus Replication; Zidovudine | 2001 |